Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
Innovation & Entrepreneurship
Strategy / MBA Resources
Case Study SWOT Analysis Solution
Case Study Description of Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets
This case explores the difficulties involved in commercialising vaccines in low-income settings. The focus is the dengue vaccine, launched at the end of 2015, which was first commercialised in emerging markets. It considers issues of affordability and distribution, higlighting the need for business model innovation in all industries.
Swot Analysis of "Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets" written by Philip Parker, Pierfitte Marion includes – strengths weakness that are internal strategic factors of the organization, and opportunities and threats that Vaccine Dengue facing as an external strategic factors. Some of the topics covered in Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets case study are - Strategic Management Strategies, Health and Innovation & Entrepreneurship.
Some of the macro environment factors that can be used to understand the Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets casestudy better are - – there is backlash against globalization, digital marketing is dominated by two big players Facebook and Google, there is increasing trade war between United States & China, customer relationship management is fast transforming because of increasing concerns over data privacy, increasing inequality as vast percentage of new income is going to the top 1%, competitive advantages are harder to sustain because of technology dispersion, increasing government debt because of Covid-19 spendings,
talent flight as more people leaving formal jobs, increasing energy prices, etc
Introduction to SWOT Analysis of Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets
SWOT stands for an organization’s Strengths, Weaknesses, Opportunities and Threats . At Oak Spring University , we believe that protagonist in Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets case study can use SWOT analysis as a strategic management tool to assess the current internal strengths and weaknesses of the Vaccine Dengue, and to figure out the opportunities and threats in the macro environment – technological, environmental, political, economic, social, demographic, etc in which Vaccine Dengue operates in.
According to Harvard Business Review, 75% of the managers use SWOT analysis for various purposes such as – evaluating current scenario, strategic planning, new venture feasibility, personal growth goals, new market entry, Go To market strategies, portfolio management and strategic trade-off assessment, organizational restructuring, etc.
SWOT Objectives / Importance of SWOT Analysis and SWOT Matrix
SWOT analysis of Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets can be done for the following purposes –
1. Strategic planning using facts provided in Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets case study
2. Improving business portfolio management of Vaccine Dengue
3. Assessing feasibility of the new initiative in Innovation & Entrepreneurship field.
4. Making a Innovation & Entrepreneurship topic specific business decision
5. Set goals for the organization
6. Organizational restructuring of Vaccine Dengue
Strengths Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets | Internal Strategic Factors
What are Strengths in SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The strengths of Vaccine Dengue in Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets Harvard Business Review case study are -
Successful track record of launching new products
– Vaccine Dengue has launched numerous new products in last few years, keeping in mind evolving customer preferences and competitive pressures. Vaccine Dengue has effective processes in place that helps in exploring new product needs, doing quick pilot testing, and then launching the products quickly using its extensive distribution network.
Learning organization
- Vaccine Dengue is a learning organization. It has inculcated three key characters of learning organization in its processes and operations – exploration, creativity, and expansiveness. The work place at Vaccine Dengue is open place that encourages instructiveness, ideation, open minded discussions, and creativity. Employees and leaders in Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets Harvard Business Review case study emphasize – knowledge, initiative, and innovation.
Digital Transformation in Innovation & Entrepreneurship segment
- digital transformation varies from industry to industry. For Vaccine Dengue digital transformation journey comprises differing goals based on market maturity, customer technology acceptance, and organizational culture. Vaccine Dengue has successfully integrated the four key components of digital transformation – digital integration in processes, digital integration in marketing and customer relationship management, digital integration into the value chain, and using technology to explore new products and market opportunities.
Innovation driven organization
– Vaccine Dengue is one of the most innovative firm in sector. Manager in Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets Harvard Business Review case study can use Clayton Christensen Disruptive Innovation strategies to further increase the scale of innovtions in the organization.
Sustainable margins compare to other players in Innovation & Entrepreneurship industry
– Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets firm has clearly differentiated products in the market place. This has enabled Vaccine Dengue to fetch slight price premium compare to the competitors in the Innovation & Entrepreneurship industry. The sustainable margins have also helped Vaccine Dengue to invest into research and development (R&D) and innovation.
Ability to lead change in Innovation & Entrepreneurship field
– Vaccine Dengue is one of the leading players in its industry. Over the years it has not only transformed the business landscape in its segment but also across the whole industry. The ability to lead change has enabled Vaccine Dengue in – penetrating new markets, reaching out to new customers, and providing different value propositions to different customers in the international markets.
Analytics focus
– Vaccine Dengue is putting a lot of focus on utilizing the power of analytics in business decision making. This has put it among the leading players in the industry. The technology infrastructure suggested by Philip Parker, Pierfitte Marion can also help it to harness the power of analytics for – marketing optimization, demand forecasting, customer relationship management, inventory management, information sharing across the value chain etc.
Training and development
– Vaccine Dengue has one of the best training and development program in the industry. The effectiveness of the training programs can be measured in Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets Harvard Business Review case study by analyzing – employees retention, in-house promotion, loyalty, new venture initiation, lack of conflict, and high level of both employees and customer engagement.
High brand equity
– Vaccine Dengue has strong brand awareness and brand recognition among both - the exiting customers and potential new customers. Strong brand equity has enabled Vaccine Dengue to keep acquiring new customers and building profitable relationship with both the new and loyal customers.
Highly skilled collaborators
– Vaccine Dengue has highly efficient outsourcing and offshoring strategy. It has resulted in greater operational flexibility and bringing down the costs in highly price sensitive segment. Secondly the value chain collaborators of the firm in Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets HBR case study have helped the firm to develop new products and bring them quickly to the marketplace.
Operational resilience
– The operational resilience strategy in the Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets Harvard Business Review case study comprises – understanding the underlying the factors in the industry, building diversified operations across different geographies so that disruption in one part of the world doesn’t impact the overall performance of the firm, and integrating the various business operations and processes through its digital transformation drive.
High switching costs
– The high switching costs that Vaccine Dengue has built up over years in its products and services combo offer has resulted in high retention of customers, lower marketing costs, and greater ability of the firm to focus on its customers.
Weaknesses Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets | Internal Strategic Factors
What are Weaknesses in SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The weaknesses of Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets are -
Increasing silos among functional specialists
– The organizational structure of Vaccine Dengue is dominated by functional specialists. It is not different from other players in the Innovation & Entrepreneurship segment. Vaccine Dengue needs to de-silo the office environment to harness the true potential of its workforce. Secondly the de-silo will also help Vaccine Dengue to focus more on services rather than just following the product oriented approach.
Products dominated business model
– Even though Vaccine Dengue has some of the most successful products in the industry, this business model has made each new product launch extremely critical for continuous financial growth of the organization. firm in the HBR case study - Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets should strive to include more intangible value offerings along with its core products and services.
High cash cycle compare to competitors
Vaccine Dengue has a high cash cycle compare to other players in the industry. It needs to shorten the cash cycle by 12% to be more competitive in the marketplace, reduce inventory costs, and be more profitable.
Workers concerns about automation
– As automation is fast increasing in the segment, Vaccine Dengue needs to come up with a strategy to reduce the workers concern regarding automation. Without a clear strategy, it could lead to disruption and uncertainty within the organization.
Slow to strategic competitive environment developments
– As Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets HBR case study mentions - Vaccine Dengue takes time to assess the upcoming competitions. This has led to missing out on atleast 2-3 big opportunities in the industry in last five years.
Interest costs
– Compare to the competition, Vaccine Dengue has borrowed money from the capital market at higher rates. It needs to restructure the interest payment and costs so that it can compete better and improve profitability.
Slow decision making process
– As mentioned earlier in the report, Vaccine Dengue has a very deliberative decision making approach. This approach has resulted in prudent decisions, but it has also resulted in missing opportunities in the industry over the last five years. Vaccine Dengue even though has strong showing on digital transformation primary two stages, it has struggled to capitalize the power of digital transformation in marketing efforts and new venture efforts.
High dependence on star products
– The top 2 products and services of the firm as mentioned in the Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets HBR case study still accounts for major business revenue. This dependence on star products in has resulted into insufficient focus on developing new products, even though Vaccine Dengue has relatively successful track record of launching new products.
High dependence on existing supply chain
– The disruption in the global supply chains because of the Covid-19 pandemic and blockage of the Suez Canal illustrated the fragile nature of Vaccine Dengue supply chain. Even after few cautionary changes mentioned in the HBR case study - Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets, it is still heavily dependent upon the existing supply chain. The existing supply chain though brings in cost efficiencies but it has left Vaccine Dengue vulnerable to further global disruptions in South East Asia.
No frontier risks strategy
– After analyzing the HBR case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets, it seems that company is thinking about the frontier risks that can impact Innovation & Entrepreneurship strategy. But it has very little resources allocation to manage the risks emerging from events such as natural disasters, climate change, melting of permafrost, tacking the rise of artificial intelligence, opportunities and threats emerging from commercialization of space etc.
Need for greater diversity
– Vaccine Dengue has taken concrete steps on diversity, equity, and inclusion. But the efforts so far has resulted in limited success. It needs to expand the recruitment and selection process to hire more people from the minorities and underprivileged background.
Opportunities Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets | External Strategic Factors
What are Opportunities in the SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The opportunities highlighted in the Harvard Business Review case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets are -
Using analytics as competitive advantage
– Vaccine Dengue has spent a significant amount of money and effort to integrate analytics and machine learning into its operations in the sector. This continuous investment in analytics has enabled, as illustrated in the Harvard case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets - to build a competitive advantage using analytics. The analytics driven competitive advantage can help Vaccine Dengue to build faster Go To Market strategies, better consumer insights, developing relevant product features, and building a highly efficient supply chain.
Manufacturing automation
– Vaccine Dengue can use the latest technology developments to improve its manufacturing and designing process in Innovation & Entrepreneurship segment. It can use CAD and 3D printing to build a quick prototype and pilot testing products. It can leverage automation using machine learning and artificial intelligence to do faster production at lowers costs, and it can leverage the growth in satellite and tracking technologies to improve inventory management, transportation, and shipping.
Harnessing reconfiguration of the global supply chains
– As the trade war between US and China heats up in the coming years, Vaccine Dengue can build a diversified supply chain model across various countries in - South East Asia, India, and other parts of the world. This reconfiguration of global supply chain can help, as suggested in case study, Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets, to buy more products closer to the markets, and it can leverage its size and influence to get better deal from the local markets.
Developing new processes and practices
– Vaccine Dengue can develop new processes and procedures in Innovation & Entrepreneurship industry using technology such as automation using artificial intelligence, real time transportation and products tracking, 3D modeling for concept development and new products pilot testing etc.
Buying journey improvements
– Vaccine Dengue can improve the customer journey of consumers in the industry by using analytics and artificial intelligence. Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets suggest that firm can provide automated chats to help consumers solve their own problems, provide online suggestions to get maximum out of the products and services, and help consumers to build a community where they can interact with each other to develop new features and uses.
Use of Bitcoin and other crypto currencies for transactions
– The popularity of Bitcoin and other crypto currencies as asset class and medium of transaction has opened new opportunities for Vaccine Dengue in the consumer business. Now Vaccine Dengue can target international markets with far fewer capital restrictions requirements than the existing system.
Lowering marketing communication costs
– 5G expansion will open new opportunities for Vaccine Dengue in the field of marketing communication. It will bring down the cost of doing business, provide technology platform to build new products in the Innovation & Entrepreneurship segment, and it will provide faster access to the consumers.
Building a culture of innovation
– managers at Vaccine Dengue can make experimentation a productive activity and build a culture of innovation using approaches such as – mining transaction data, A/B testing of websites and selling platforms, engaging potential customers over various needs, and building on small ideas in the Innovation & Entrepreneurship segment.
Leveraging digital technologies
– Vaccine Dengue can leverage digital technologies such as artificial intelligence and machine learning to automate the production process, customer analytics to get better insights into consumer behavior, realtime digital dashboards to get better sales tracking, logistics and transportation, product tracking, etc.
Low interest rates
– Even though inflation is raising its head in most developed economies, Vaccine Dengue can still utilize the low interest rates to borrow money for capital investment. Secondly it can also use the increase of government spending in infrastructure projects to get new business.
Better consumer reach
– The expansion of the 5G network will help Vaccine Dengue to increase its market reach. Vaccine Dengue will be able to reach out to new customers. Secondly 5G will also provide technology framework to build new tools and products that can help more immersive consumer experience and faster consumer journey.
Learning at scale
– Online learning technologies has now opened space for Vaccine Dengue to conduct training and development for its employees across the world. This will result in not only reducing the cost of training but also help employees in different part of the world to integrate with the headquarter work culture, ethos, and standards.
Creating value in data economy
– The success of analytics program of Vaccine Dengue has opened avenues for new revenue streams for the organization in the industry. This can help Vaccine Dengue to build a more holistic ecosystem as suggested in the Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets case study. Vaccine Dengue can build new products and services such as - data insight services, data privacy related products, data based consulting services, etc.
Threats Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets External Strategic Factors
What are Threats in the SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The threats mentioned in the HBR case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets are -
Barriers of entry lowering
– As technology is more democratized, the barriers to entry in the industry are lowering. It can presents Vaccine Dengue with greater competitive threats in the near to medium future. Secondly it will also put downward pressure on pricing throughout the sector.
Easy access to finance
– Easy access to finance in Innovation & Entrepreneurship field will also reduce the barriers to entry in the industry, thus putting downward pressure on the prices because of increasing competition. Vaccine Dengue can utilize it by borrowing at lower rates and invest it into research and development, capital expenditure to fortify its core competitive advantage.
Learning curve for new practices
– As the technology based on artificial intelligence and machine learning platform is getting complex, as highlighted in case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets, Vaccine Dengue may face longer learning curve for training and development of existing employees. This can open space for more nimble competitors in the field of Innovation & Entrepreneurship .
Stagnating economy with rate increase
– Vaccine Dengue can face lack of demand in the market place because of Fed actions to reduce inflation. This can lead to sluggish growth in the economy, lower demands, lower investments, higher borrowing costs, and consolidation in the field.
New competition
– After the dotcom bust of 2001, financial crisis of 2008-09, the business formation in US economy had declined. But in 2020 alone, there are more than 1.5 million new business applications in United States. This can lead to greater competition for Vaccine Dengue in the Innovation & Entrepreneurship sector and impact the bottomline of the organization.
Regulatory challenges
– Vaccine Dengue needs to prepare for regulatory challenges as consumer protection groups and other pressure groups are vigorously advocating for more regulations on big business - to reduce inequality, to create a level playing field, to product data privacy and consumer privacy, to reduce the influence of big money on democratic institutions, etc. This can lead to significant changes in the Innovation & Entrepreneurship industry regulations.
Trade war between China and United States
– The trade war between two of the biggest economies can hugely impact the opportunities for Vaccine Dengue in the Innovation & Entrepreneurship industry. The Innovation & Entrepreneurship industry is already at various protected from local competition in China, with the rise of trade war the protection levels may go up. This presents a clear threat of current business model in Chinese market.
Technology disruption because of hacks, piracy etc
– The colonial pipeline illustrated, how vulnerable modern organization are to international hackers, miscreants, and disruptors. The cyber security interruption, data leaks, etc can seriously jeopardize the future growth of the organization.
Aging population
– As the populations of most advanced economies are aging, it will lead to high social security costs, higher savings among population, and lower demand for goods and services in the economy. The household savings in US, France, UK, Germany, and Japan are growing faster than predicted because of uncertainty caused by pandemic.
Shortening product life cycle
– it is one of the major threat that Vaccine Dengue is facing in Innovation & Entrepreneurship sector. It can lead to higher research and development costs, higher marketing expenses, lower customer loyalty, etc.
Backlash against dominant players
– US Congress and other legislative arms of the government are getting tough on big business especially technology companies. The digital arm of Vaccine Dengue business can come under increasing regulations regarding data privacy, data security, etc.
Increasing international competition and downward pressure on margins
– Apart from technology driven competitive advantage dilution, Vaccine Dengue can face downward pressure on margins from increasing competition from international players. The international players have stable revenue in their home market and can use those resources to penetrate prominent markets illustrated in HBR case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets .
Increasing wage structure of Vaccine Dengue
– Post Covid-19 there is a sharp increase in the wages especially in the jobs that require interaction with people. The increasing wages can put downward pressure on the margins of Vaccine Dengue.
Weighted SWOT Analysis of Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets Template, Example
Not all factors mentioned under the Strengths, Weakness, Opportunities, and Threats quadrants in the SWOT Analysis are equal. Managers in the HBR case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets needs to zero down on the relative importance of each factor mentioned in the Strengths, Weakness, Opportunities, and Threats quadrants.
We can provide the relative importance to each factor by assigning relative weights. Weighted SWOT analysis process is a three stage process –
First stage for doing weighted SWOT analysis of the case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets is to rank the strengths and weaknesses of the organization. This will help you to assess the most important strengths and weaknesses of the firm and which one of the strengths and weaknesses mentioned in the initial lists are marginal and can be left out.
Second stage for conducting weighted SWOT analysis of the Harvard case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets is to give probabilities to the external strategic factors thus better understanding the opportunities and threats arising out of macro environment changes and developments.
Third stage of constructing weighted SWOT analysis of Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets is to provide strategic recommendations includes – joining likelihood of external strategic factors such as opportunities and threats to the internal strategic factors – strengths and weaknesses. You should start with external factors as they will provide the direction of the overall industry. Secondly by joining probabilities with internal strategic factors can help the company not only strategic fit but also the most probably strategic trade-off that Vaccine Dengue needs to make to build a sustainable competitive advantage.
Feel free to connect with us if you need business research.
You can download Excel Template of Case Study Solution & Analysis of Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets
